The Safety and Effectiveness of Didanosine Plus Stavudine Plus Delavirdine Mesylate Plus MKC-442 in HIV-Infected Patients Who Have Not Had Success With Protease Inhibitors

NCT00002420 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

25

Enrollment

INDUSTRY

Sponsor class

Conditions

HIV Infections

Interventions

DRUG: Emivirine
DRUG: Hydroxyurea
DRUG: Delavirdine mesylate
DRUG: Stavudine
DRUG: Didanosine

Sponsor

Bristol-Myers Squibb

Collaborators

[object Object]
[object Object]